Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
99 hedge funds and large institutions have $1.2B invested in Karuna Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 41 increasing their positions, 15 reducing their positions, and 18 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
173% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 15
89% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 18
21% more capital invested
Capital invested by funds: $997M → $1.2B (+$207M)
16% more funds holding
Funds holding: 85 → 99 (+14)
13.22% more ownership
Funds ownership: 50.9% → 64.12% (+13%)
88% less call options, than puts
Call options by funds: $532K | Put options by funds: $4.61M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$93.1M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$58.7M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$40.6M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
+$28.7M |
| 5 |
BlackRock
New York
|
+$27.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WT
Wellcome Trust
London,
United Kingdom
|
-$95M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.81M |
| 3 |
LM
Luminus Management
Houston,
Texas
|
-$7.02M |
| 4 |
AG
Artal Group
Luxembourg
|
-$3.77M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.82M |
KRTX Hedge Fund Activity: Q1 2020 in Review
99 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q1 2020, worth a combined $1.2B — up 21% from $997M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new KRTX positions and 18 closed out — a net gain of 16 holders — while 41 added to existing stakes and 15 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $93.1M. The largest seller was Wellcome Trust, exiting entirely with an estimated $95M sold.
- 99 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q1 2020, up from 85 in Q4 2019.
- Funds reported $1.2B of Karuna Therapeutics, Inc. Common Stock stock for Q1 2020, up 21% quarter-over-quarter.
- 34 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q1 2020 and 18 closed out, a net change of +16 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q1 2020 was T. Rowe Price Associates, an estimated $93.1M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q1 2020 was Wellcome Trust, an estimated $95M sold.
Based on aggregated 13F filings for Q1 2020.